Sign in to view content

Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy

Hani Salehi-Had, MD, FASRS

Video
Published 2023

Related

Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2021
Level of Diabetic Retinopathy Severity Correlates to Degree of Quadrant Asymmetry in Both Single and Averaged Imaged OCTA Metrics
Jesse J Jung, MD, FASRS
Annual Meeting Talks
2022
Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more